Navigation Links
ASH and HVO partner to launch hematology program in Peru
Date:3/27/2009

(WASHINGTON, March 27, 2009) Following the success of a program established in Uganda last year, the American Society of Hematology (ASH) and Health Volunteers Overseas (HVO) have again partnered to launch a new hematology program together with the Peruvian Social Security Health System, Empresa De Seguros De Salud (EsSalud). The goal of this program is to improve the hematology training of clinicians, laboratory technicians, technologists, and students. This training will take place at hospitals located in Lima, Arequipa, and Cusco.

"We are enthusiastic to launch a new ASH/HVO hematology program in Peru," said Enrico M. Novelli, MD, director of the Peru program. "This is a great teaching and cultural exchange opportunity for ASH hematologist/oncologists, hematopathologists, and laboratory-based scientists with an expertise in areas such as bone marrow transplantation, coagulation disorders, lymphoproliferative disorders, or blood banking."

Volunteers will provide didactic and hands-on training in both the clinical and laboratory aspects of hematology to undergraduate medical and laboratory students, postgraduates, fellows, and staff. Volunteers will also assist in evaluating postgraduate fellow projects and aid in improving communication between the lab staff and clinicians.

Both pediatric or adult hematology/oncology clinicians and laboratory-based scientists are welcomed for assignments of one to four weeks. Volunteers must be board certified in hematology and/or blood banking. Individuals with a PhD must be certified in hematopathology or pathology with demonstrated experience in hematopathology. Applicants must be members of both ASH and HVO to be considered for this program, and volunteers from outside the United States are encouraged to apply. Although a working knowledge of Spanish is very helpful, it is not a requirement for this program. This site is not suitable for trainees.


'/>"/>

Contact: Patrick C. Irelan
pirelan@hematology.org
202-776-0544
American Society of Hematology
Source:Eurekalert

0

GOOD

Page: 1

Related medicine news :

1. ASH and HVO Partner to Launch Hematology Program in Peru
2. Prince William Health System and Novant Health Agree on Partnership to Expand Quality Healthcare in Northern Virginia
3. Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners
4. Partnership for Prescription Assistance Prepared to Help Tennessee Workers Hurt by Recession
5. InterComponentWare and CitiusTech Partner on eHealth Integration Services
6. AmeriCares and International Medical Corps Partner to Bring Lifesaving Aid to Chad
7. TRICAST, Inc. and Gorman Health Group Form Partnership to Fully Support Medicare Part D Oversight
8. Physicians Practice and Rose Medical Center Partner to Improve Patient Care in the Denver Metro Area
9. CareTech Solutions Launches Robust Service Desk Solution to Support Clinical Applications and Technology within Continuum Health Partners Hospitals
10. Enloe Medical Center Partners with Carefx to Help Clinicians Quickly, Easily Access Diverse Patient Information
11. CareOregon and Health Integrated Partner to Enhance Services for Oregonians with Chronic Illness
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 1RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 2RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 3RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 4Injection Reverses Heart Attack Damage 4771 1Injection Reverses Heart Attack Damage 4771 2Injection Reverses Heart Attack Damage 4771 3Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 1Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 2Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 3
Other Medicine Technology:Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 2Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 3Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 4Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 5Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 6Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 2Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 3Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 4Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 5Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 6